Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMTREA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Non-small cell lung cancer (NSCLC) with high PD-L1 expression (Trial 1),Advanced or metastatic NSCLC after prior chemotherapy (Trial 2)
Prevention of pregnancy (FDA-approved)
Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of 2.5 to 4 hours; prolonged in renal impairment (up to 6–12 hours in severe impairment).
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily metabolized by CYP3A4 and CYP2D6; minor contributions from CYP2C9 and CYP2C19.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal (approximately 70% as unchanged drug), with biliary/fecal excretion accounting for the remainder. Less than 5% metabolized.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Approximately 20% bound to plasma proteins (albumin).
~99% bound to serum albumin and sex hormone-binding globulin.
0.3–0.4 L/kg; indicates distribution primarily into extracellular fluid.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 30–40% due to incomplete absorption and first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
For GFR 30-59 m L/min: reduce to 750 mg/m2; for GFR 15-29 m L/min: reduce to 500 mg/m2; for GFR <15 m L/min or dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use due to lack of data.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment based solely on age; monitor renal function and adjust accordingly.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal. Monitor for signs and symptoms. Withhold or permanently discontinue based on severity.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Risk of immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and infusion-related reactions. Evaluate liver and renal function, thyroid function, and pregnancy status before initiation.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
None known.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Grapefruit juice may slightly increase estrogen exposure but not clinically significant. Avoid St. John's Wort as it reduces efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pimtrea (ethinyl estradiol and drospirenone) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects from population-based cohort studies, but data are limited. Second and third trimester exposure: may increase risk of fetal harm, including cardiovascular and genitourinary anomalies, due to hormonal effects. Use only if clearly needed after weighing risks; discontinue if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Ethinyl estradiol and drospirenone are excreted in human milk in small amounts; estimated M/P ratio for drospirenone is approximately 0.37. Combination hormonal contraceptives may reduce milk production and quality. Not recommended during lactation, especially in the first 6 months postpartum. Use alternative contraception.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Pimtrea is contraindicated during pregnancy; no dosing adjustments applicable. Pharmacokinetic changes during pregnancy (e.g., increased hepatic metabolism, volume of distribution) may reduce efficacy; however, use is not recommended. If inadvertently exposed, discontinue drug.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Pimtrea (desogestrel/ethinyl estradiol) is a monophasic combined oral contraceptive. Counsel patients that missed pills increase pregnancy risk. Use with caution in smokers over 35 due to thromboembolism risk. Consider ARB/ACEI interaction for blood pressure control. No need for routine monitoring if asymptomatic.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time; if missed, refer to package insert for instructions.,Do not smoke while taking this pill, especially if over 35.,Report sudden severe headache, chest pain, leg pain, or vision changes.,May cause nausea, breast tenderness, or breakthrough bleeding initially.,Protection against pregnancy starts after 7 consecutive days of correct use.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMTREA vs AFIRMELLE, answered by our medical review team.
PIMTREA is a Oral Contraceptive that works by PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMTREA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMTREA is: Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMTREA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMTREA is classified as Category C. Pimtrea (ethinyl estradiol and drospirenone) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects from population-based cohort studie. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.